Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 25/2/2021
SIETES contiene 93212 citas

 1 a 20 de 111 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Waxmonsky JG, Pelham W 3rd, Campa A, Waschbusch DA, Li T, Marshall R, Babocsai L, Humphery H, Gnagy E, Swanson J, Hanc T, Fallahazad N, Pelham WE 4th. A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. J Am Acad Child Adolesc Psychiatry 2019:29 de agosto. [Ref.ID 103191]
2.Enlace a cita original Cita con resumen
Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues A, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow C-M, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. The Lancet Diabetes & Endocrinology 2019:6 de marzo. [Ref.ID 103052]
4. Cita con resumen
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424-34. [Ref.ID 100458]
5. Cita con resumen
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, Andreasen AH, Jensen CB, DeFronzo RA, for the NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes. The SCALE diabetes randomized clinical trial. JAMA 2015;314:687-99. [Ref.ID 99409]
6. Cita con resumen
Anónimo. Liraglutide (Saxenda) for weight loss. Med Lett Drugs Ther 2015;57:7-8. [Ref.ID 99215]
7. Cita con resumen
Schumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukaris AG, Kiyota N, Taylor MH, Kim S-B, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radiodiodine-refractory thyroid cancer. N Engl J Med 2015;372:621-30. [Ref.ID 98795]
8. Cita con resumen
Anónimo. Thyroid cancer treatment performs well in clinical trial, FDA approval expected. DIA Daily 2014:13 de febrero. [Ref.ID 98776]
Astrup A, Madsbad S, Breum L, Jensen TJ. Under-reporting of adverse effects of tesofensine. Lancet 2013;382:127. [Ref.ID 95827]
11.Tiene citas relacionadas
van der Graaf W, Judson I, Dei Tos AP, Litiere S, Blay J-Y. Pazopanib for metastatic soft-tissue sarcoma. Authors' reply. Lancet 2012;380:801-2. [Ref.ID 93715]
12.Tiene citas relacionadas
Endo M, Nielsen TO. Pazopanib for metastatic soft-tissue sarcoma. Lancet 2012;380:801. [Ref.ID 93714]
13. Cita con resumen
Anónimo. FDA approves Cometriq to treat rare type of thyroid cancer. U.S. Food and Drug Administration 2012:29 de noviembre. [Ref.ID 93268]
14. Cita con resumen
Anónimo. FDA clears advanced-colorectal cancer treatment. DIA Daily 2012:28 de septiembre. [Ref.ID 93061]
15.Tiene citas relacionadas Cita con resumen
van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P, on behalf of the EORTC Soft Tissue and Bone Sarcoma Group and the PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86. [Ref.ID 93018]
16.Tiene citas relacionadas
Bramwell VHC. Pazopanib and the treatment palette for soft-tissue sarcoma. Lancet 2012;379:1854-6. [Ref.ID 93011]
17. Cita con resumen
18.Tiene citas relacionadas Cita con resumen
Vilsboll T, Christensen M, Junker AE, Knopf FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.. BMJ 2012;344:14. [Ref.ID 92292]
19.Tiene citas relacionadas Cita con resumen
Padwal R. Glucagon-like peptide-1 agonists. BMJ 2012;344:7. [Ref.ID 92290]
20. Cita con resumen
Anónimo. Vildagliptin – a new oral antidiabetic agent. Signal 2011:13-4. [Ref.ID 91692]
Seleccionar todas
 1 a 20 de 111 siguiente >>